The majority of relevant studies have argued that CRLF2 overexpression is correlated with the poor prognosis of B-ALL patients, especially those with high-risk B-ALL (2, 3, 31, 34, 37). Here, CRLF2 is linked to acute lymphoblastic leukemia.